Policy
Federal Guidance Reshapes Fertility Benefits Market Strategy
New DOL rules clarify excepted benefit pathways for fertility coverage. Progyny's 9% stock drop signals concerns about margin compression as drug costs fall.
Articles by Ela Buczynska
Fertility Care Business Contributor
Policy
White House-EMD Serono IVF Deal Signals Regulatory Shift for Fertility Industry
White House-EMD Serono IVF deal cuts drug costs 84%. Analysis of competitive impacts, clinic valuation risks, and regulatory implications for fertility investors.